,0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25
0,[1],"ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9",,,,,,,,,,,,,,,,,,,,,,,,
1,[2],"Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million.",,,,,,,,,,,,,,,,,,,,,,,,
2,[3],Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million.,,,,,,,,,,,,,,,,,,,,,,,,
3,[4],"Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million.",,,,,,,,,,,,,,,,,,,,,,,,
4,[5],"Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million.",,,,,,,,,,,,,,,,,,,,,,,,
5,[6],Includes Mylan defense-related fees of $15.6 million.,,,,,,,,,,,,,,,,,,,,,,,,
6,[7],"(4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees.",,,,,,,,,,,,,,,,,,,,,,,,
7,[8],Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million.,,,,,,,,,,,,,,,,,,,,,,,,
8,[9],"Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million.",,,,,,,,,,,,,,,,,,,,,,,,
9,[10],The sum of individual per share amounts may not equal due to rounding.,,,,,,,,,,,,,,,,,,,,,,,,
10,"Consolidated Statements of Income - USD ($)  shares in Millions, $ in Millions",3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,3 Months Ended,6 Months Ended,6 Months Ended,12 Months Ended,12 Months Ended,12 Months Ended
11,"Consolidated Statements of Income - USD ($)  shares in Millions, $ in Millions","Dec. 31, 2016",[1],"Oct. 01, 2016",[2],"Jul. 02, 2016",[3],"Apr. 02, 2016",[4],"Dec. 31, 2015","Dec. 31, 2015","Sep. 26, 2015",[6],"Jun. 27, 2015",[7],"Mar. 28, 2015",[8],"Dec. 27, 2014","Dec. 27, 2014","Sep. 27, 2014","Sep. 27, 2014","Dec. 31, 2015","Dec. 27, 2014","Dec. 31, 2016","Jun. 27, 2015","Jun. 28, 2014"
12,Income Statement [Abstract],,,,,,,,,,,,,,,,,,,,,,,,,
13,Net sales,"$ 1,331.2",,"$ 1,261.6",,"$ 1,340.5",,"$ 1,347.3",,"$ 1,359.1",[5],"$ 1,273.1",,"$ 1,415.2",,$ 967.2,,$ 985.1,[9],$ 859.6,,"$ 2,632.2","$ 1,844.7","$ 5,280.6","$ 4,227.1","$ 3,914.1"
14,Cost of sales,,,,,,,,,,,,,,,,,,,,,1553.3,1170.9,3228.8,2582.9,2462.0
15,Gross profit,487.7,,484.5,,546.5,,533.1,,543.7,[5],535.2,,601.0,,369.4,,369.7,[9],304.1,,1078.9,673.8,2051.8,1644.2,1452.1
16,Operating expenses,,,,,,,,,,,,,,,,,,,,,,,,,
17,Distribution,,,,,,,,,,,,,,,,,,,,,47.9,29.2,88.3,67.7,55.3
18,Research and development,,,,,,,,,,,,,,,,,,,,,88.2,89.8,184.0,187.8,152.5
19,Selling,,,,,,,,,,,,,,,,,,,,,325.9,95.3,665.0,319.0,208.6
20,Administration,,,,,,,,,,,,,,,,,,,,,306.8,165.6,452.2,385.3,411.3
21,Impairment charges,,,,,,,,,,,,,,,,,,,,,215.6,0.0,2631.0,6.8,6.0
22,Restructuring,,,,,,,,,24.7,,,,,,,,,,,,26.9,4.2,31.0,5.1,47.0
23,Total operating expenses,,,,,,,,,,,,,,,,,,,,,1011.3,384.1,4051.5,971.7,880.7
24,Operating income (loss),,,,,,,,,,,,,,,,,,,,,67.6,289.7,"(1,999.7)",672.5,571.4
25,Tysabri® royalty stream - change in fair value,"(1,115.6)",,377.4,,910.8,,204.4,,(116.6),[5],(173.8),,69.2,,(100.8),,105.8,[9],(58.9),,(57.3),(46.9),2608.2,(78.5),(26.6)
26,"Interest expense, net",,,,,,,,,,,,,,,,,,,,,89.9,56.7,216.6,146.0,103.5
27,"Other expense, net",,,,,,,,,,,,,,,,,,,,,25.2,60.3,22.7,334.2,25.1
28,Loss on extinguishment of debt,,,,,,,,,,,,,,,,,9.6,,,,0.9,9.6,1.1,10.5,165.8
29,Income (loss) before income taxes,,,,,,,,,,,,,,,,,,,,,8.9,210.0,"(4,848.3)",260.3,303.6
30,Income tax expense (benefit),,,,,,,,,,,,,,,,,,,,,(33.6),29.4,(835.5),124.2,70.8
31,Net income (loss),"$ (1,359.1)",,"$ (1,590.2)",,$ (534.3),,$ (529.2),,$ (218.4),[5],$ 260.9,,$ (22.2),,$ (22.2),,$ 151.1,[9],$ 29.4,,$ 42.5,$ 180.6,"$ (4,012.8)",$ 136.1,$ 232.8
32,Basic,,,,,,,,,,,,,,,,,,,,,,,,,
33,Basic (in dollars per share),$ (9.48),[10],$ (11.10),[10],$ (3.73),[10],$ (3.70),[10],$ (1.51),"[5],[10]",$ 1.78,[10],$ (0.15),[10],$ (0.16),[10],$ 1.11,"[9],[10]",$ 0.22,[10],$ 0.29,$ 1.34,$ (28.01),$ 0.97,$ 2.02
34,Diluted,,,,,,,,,,,,,,,,,,,,,,,,,
35,Diluted (in dollars per share),$ (9.48),[10],$ (11.10),[10],$ (3.73),[10],$ (3.70),[10],$ (1.51),"[5],[10]",$ 1.78,[10],$ (0.15),[10],$ (0.16),[10],$ 1.10,"[9],[10]",$ 0.22,[10],$ 0.29,$ 1.34,$ (28.01),$ 0.97,$ 2.01
36,Weighted-average shares outstanding,,,,,,,,,,,,,,,,,,,,,,,,,
37,Basic (in shares),143.4,,143.3,,143.2,,143.2,,144.9,[5],146.3,,146.3,,140.8,,136.3,[9],133.9,,145.6,135.1,143.3,139.3,115.1
38,Diluted (in shares),143.4,,143.3,,143.2,,143.2,,144.9,[5],146.9,,146.3,,140.8,,136.8,[9],134.4,,146.1,135.6,143.3,139.8,115.6
39,Dividends declared per share (in dollars per share),,,,,,,,,,,,,,,,,,,,,$ 0.25,$ 0.21,$ 0.580,$ 0.4600,$ 0.3900
40,,,,,,,,,,,,,,,,,,,,,,,,,,
41,"[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding.","[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9 [2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million. [3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million. [4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million. [5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million. [6] Includes Mylan defense-related fees of $15.6 million. [7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees. [8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million. [9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million. [10] The sum of individual per share amounts may not equal due to rounding."
